Search Results

BC Platforms, a global leader in real world data, healthcare data management, and analytics, announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven medicine.

BC Platforms, a global leader in healthcare data management and analytics, announces the appointment of Mikaela Bruhammar, an experienced life sciences executive, as the company’s Chief Operating Officer, Markets.

Berlin Cures announced the successful completion of patient screening for its pan-European Phase II trial of BC 007, a novel therapeutic candidate for the treatment of Long COVID.

BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has closed a CHF 20 million (approx. USD 20 million) financing round.

BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) in China.

BioCity Biopharma announced the dosing of the first patient in a Phase 1a/1b clinical trial of its first-in-class CDH3 antibody drug conjugate, BC3195 in China.

BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity’s BC3402, a monoclonal antibody targeting the T cell immunoglobulin and mucin domain-containing protein 3, also known as TIM-3, in combination with AstraZeneca’s anti-PD-L1 mAb IMFINZI for the treatment of advanced hepatocellular carcinoma.